Biognosys
Private Company
Total funding raised: $60.5M
Overview
Founded in 2008 and headquartered in Schlieren, Switzerland, Biognosys has established itself as a premier proteomics contract research organization (CRO) and technology provider. The company's core strength lies in its patented mass spectrometry workflows and its flagship Spectronaut software suite, which enable deep, quantitative analysis of thousands of proteins across thousands of samples. Through strategic partnerships and continuous innovation, Biognosys is expanding its service offerings into multiomics and high-throughput applications, positioning itself as a critical enabler for biomarker discovery and precision medicine.
Technology Platform
Proprietary mass spectrometry workflows (DIA), AI-powered software suite (Spectronaut), and sample preparation kits for next-generation proteomics.
Funding History
5Opportunities
Risk Factors
Competitive Landscape
Competes with other specialized proteomics CROs (e.g., Olink, SomaLogic via different technologies), large life science tools companies (e.g., Thermo Fisher, Agilent), and the in-house capabilities of large pharma. Its differentiation lies in its depth of DIA expertise, integrated software-hardware ecosystem, and focus on large-scale, unbiased discovery.